Ingenix raises €13m to scale AI drug development model
AI company Ingenix has announced it has raised €13 million to scale its drug development model.
Ingenix says its Biological Reasoning Engine overcomes structural problems in AI drug development, integrating best-in-class models across modalities and biological scales.
The model was applied to a dual-payload ADC prioritisation problem for an oncology biotech, with Ingenix claiming the engine generated insights in minutes that would have taken the biotech years of research.
The seed-extension funding round, led by Sofinnova Partners, will allow Ingenix to scale its Biological Reasoning Engine and broaden the company’s work with pharma and biotech partners.
“This funding lets us extend the Biological Reasoning Engine to the partners and questions where it can do the most useful work,” said Piotr Surma, CEO and Co-Founder of Ingenix.
“We built Ingenix on the conviction that biology needs an AI architecture designed for biology and not a general-purpose model retrofitted to it. The early results have been stronger than we forecast, and we’re excited to extend the engine to a select number of partners through the Qualified Access Program.”
